AbbVie Biohaven Teva announce latest researches on migraine drugs

• Facebook
• Twitter
• Reddit
• Tumblr
• LinkedIn
• Pinterest
• RSS Feed
• Link

AHS 2022: AbbVie Biohaven Teva announce latest researches on migraine drugs

• FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
• WHO Requests More Information from China on Pediatric Clustered Pneumonia
• First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
• Cardiovascular Diseases Linked to COVID-19 Infections
• What is the difference between dopamine and dobutamine?
• How long can the patient live after heart stent surgery?

AHS 2022: AbbVie Biohaven Teva announce latest researches on migraine drugs. 

This article summarizes some of the research presented at the 64th Annual Meeting of the American Headache Society in 2022, held June 9-12 in Denver, Colorado, USA.

Founded in 1959, the American Headache Society (AHS) is a professional society dedicated to the research and treatment of headache and facial pain.

Migraine is a common chronic neurovascular disease that causes severe pain on one or both sides of the head, along with nausea, vomiting, and sensitivity to light, sound, or smell.

If left untreated, a single attack can last from 4 to 72 hours and recur repeatedly, seriously affecting the patient’s work and life.

01 Biohaven: Zavegepant Nasal Spray for Acute Migraine

Biohaven Pharmaceutical submitted 31 abstracts, including 3 oral presentations at the AHS meeting.

Report presents full Phase III data for zavegepant nasal spray as an acute treatment for migraine and presents data from a 52-week open-label extension study of Nurtec (ODT) (rimegepant) administered every other day for migraine Prophylactic treatment and as a necessary acute treatment.

Nurtec research shows the drug is safe and effective, helping nearly half of patients achieve a 100% reduction in monthly migraine days.

Zavegepant is the third-generation high-affinity, high-selectivity small molecule CGRP receptor antagonist developed by Biohaven.

In a phase II/III trial of the drug in more than 1,000 patients, the drug showed 2-hour freedom from pain and patients’ most bothersome symptoms, such as nausea, photophobia, or misophonia, on both primary endpoints. statistical advantage.

02 Teva: Ajovy injection for preventive treatment of migraine

Teva Pharmaceuticals, the U.S. subsidiary of Teva Pharmaceutical Industries, presented 8 abstracts at this meeting, presenting real-world data on the use of Ajovy (fremanezumab-vfrm) injection in different migraine patient populations, emphasizing the use of Ajovy in different clinical situations Impact on patients with specific migraine treatment needs; and provides data from a subgroup analysis of the Phase IIIb FOCUS study detailing the use of the drug in patients with refractory migraine and comorbid obesity.

Data showing that patients who received gepant for one or more months before and after starting AJOVY as add-on therapy and who had 3 or more measurements of monthly migraine days (MMD) were included in the analysis: one in the index Before the date (gepant start), one in the index (AJOVY start), one in the post-index period (gepant + happy).

At the start of AJOVY, the mean (standard deviation) of patients was 15.8 (7.4) MMD. The average time from index date to last access was 9.4 (4.5) months.

The average change in MMD from index to post-index date was -6.5 (1.0) days, a decrease of 41.1%. Five patients (9.1%) had adverse events after the index; 3 injection site reactions, 1 uveitis and 1 gastric upset.

03 Satsuma: STS101 nasal powder for acute migraine

Satsuma Pharmaceuticals submitted 5 abstracts focusing on STS101 (dihydroergotamine (DHE) nasal powder) for migraine, presenting data including long-term safety and tolerability data from phase III trials, subjects tested Impression data, nasal cavity safety data, etc.

The drug, which is being developed for the acute treatment of migraine, is a unique proprietary nasal powder formulation delivered using the company’s proprietary nasal delivery device.

04 AbbVie: Migraine portfolio Qulipta (atogepant), Ubrelvy (ubrogepant), BOTOX

AbbVie submitted 29 abstracts, including two oral presentations and one late-stage presentation, presenting data including a Phase III progressive study of atogepant in the prevention of chronic migraine that will support the submission of a supplemental new drug application (sNDA) to the FDA to Expand use of this drug.

AbbVie also presented clinical data for Ubrelvy (ubrogepant) for the acute treatment of migraine and BOTOX (onabotulinumtoxinA) for the preventive treatment of chronic migraine.

As the only pharmaceutical company to offer three products, including the preventive treatment of chronic and episodic migraine and the acute treatment of migraine, AbbVie will continue to investigate potential new indications for the three drugs to help more patients.

Reference source:

1. AbbVie, Biohaven, Teva and Satsuma Tackle Migraine at AHS

2. New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting

AHS 2022 AbbVie Biohaven Teva announce latest researches on migraine drugs

(source:internet, reference only)

Disclaimer of medicaltrend.org